share_log

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

PMGC控股公司在出售护肤品子公司后,开始了大胆的增长策略
GlobeNewswire ·  01/03 04:55

Divestiture Highlights Strategic Plans on Potential High-Impact Acquisitions

资产剥离凸显了潜在高影响力收购的战略计划

Strategic Divestment Reduces Cash Burn and Enhances Operational Efficiency

战略撤资减少了现金消耗并提高了运营效率

NEWPORT BEACH, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (formerly Elevai Labs Inc.) (the "Company" or "PMGC") (Nasdaq: ELAB) today announced its commitment to accelerating shareholder value creation and market leadership following the sale of its skincare subsidiary, Elevai Skincare. This strategic divestiture marks a significant milestone in PMGC's journey as a diversified holding company.

加利福尼亚州纽波特海滩,2025 年 1 月 2 日(GLOBE NEWSWIRE)— PMGC Holdings Inc.(前身为 Elevai Labs Inc.)(“公司” 或 “PMGC”)(纳斯达克股票代码:ELAB)今天宣布,在出售其护肤子公司Elevai Skincare后,承诺加快股东价值创造和市场领导地位。此次战略剥离标志着PMGC作为多元化控股公司发展历程中的一个重要里程碑。

The sale was executed to maximize immediate financial benefit while securing future upside through structured royalties and milestone payments. It has notably strengthened PMGC's balance sheet, reduced operational losses, and paved the way for new opportunities that align with the company's long-term vision.

此次出售旨在最大限度地提高即时财务收益,同时通过结构化特许权使用费和里程碑式付款确保未来的上行空间。它显著加强了PMGC的资产负债表,减少了运营损失,并为符合公司长期愿景的新机遇铺平了道路。

Strategic Rationale: Think Bigger, Act Bold

战略理由:大胆思考,大胆行动

The divestiture underscores PMGC's strategy to focus on acquiring transformative assets and businesses that deliver substantial growth and shareholder value. This sale frees the Company to look for bigger opportunities. Executive management's goal is not incremental improvement but exponential growth through strategic acquisitions and steadfast execution.

此次剥离凸显了PMGC的战略,即专注于收购可带来可观增长和股东价值的变革性资产和业务。此次出售使公司腾出时间寻找更大的机会。执行管理层的目标不是渐进式改进,而是通过战略收购和坚定执行实现指数级增长。

Key Financial and Operational Highlights Post Sale

售后主要财务和运营亮点

  • Burn Rate Reduction: By eliminating a loss-generating subsidiary, PMGC ensures a leaner and more focused operational framework.
  • Strengthened Financials: PMGC will receive approximately $1.1 million in Carmell Corporation stock and retains a lucrative 5% royalty on skincare revenues over the next five years, alongside milestone payment opportunities.
  • Growth Capital: Resources will now be channeled into high-potential assets, leveraging PMGC's drive and expertise in creating shareholder value.
  • 降低烧毁率:通过取消一家产生亏损的子公司,PMGC确保了更精简、更有针对性的运营框架。
  • 财务状况增强:PMGC将获得约110万美元的Carmell Corporation股票,并在未来五年内保留5%的护肤收入特许权使用费,以及里程碑式的付款机会。
  • 成长资本:现在将利用PMGC在创造股东价值方面的动力和专业知识,将资源引导到高潜力资产中。

Why It Matters to Shareholders

为什么它对股东很重要

This move demonstrates PMGC's agility in adapting to market opportunities and its unwavering commitment to delivering shareholder value. The sale of Elevai Skincare is a step toward creating a portfolio of assets that reflects the company's expansive vision and ambition.

此举表明了PMGC在适应市场机会方面的灵活性及其对为股东创造价值的坚定承诺。出售Elevai Skincare是朝着创建反映公司广阔愿景和雄心壮志的资产组合迈出的一步。

For investors, this signals a moment of transition and opportunity. As PMGC positions itself to seize larger, more impactful opportunities, shareholders can look forward to the potential for increased returns, reduced risk, and sustainable growth.

对于投资者来说,这预示着过渡和机遇的时刻。随着PMGC将自己定位为抓住更大、更具影响力的机会,股东们可以期待获得更高的回报、降低风险和可持续增长的潜力。

Looking Ahead: Growth, Diversification, and Opportunity

展望未来:增长、多元化和机遇

PMGC is actively exploring accretive acquisitions and licensing opportunities in sectors poised for significant growth. The Company is focused on identifying undervalued assets and businesses that align with a vision of building a diversified and growth-oriented holding company.

PMGC正在积极探索有望实现显著增长的行业的增值收购和许可机会。该公司专注于寻找被低估的资产和业务,这些资产和业务符合建立多元化和以增长为导向的控股公司的愿景。

PMGC Holdings Inc. will continue to expand its company portfolio with a focus on innovation, growth, and shareholder value creation. Current subsidiaries include:

PMGC Holdings Inc. 将继续扩大其公司投资组合,重点是创新、增长和股东价值创造。目前的子公司包括:

Elevai Biosciences: a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Our lead asset, EL-22, is leveraging an engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. For more information, please visit .

Elevai Biosciences:一家专注于开发和收购尖端美容药物的生物制药公司。我们的主要资产 EL-22 正在利用精心设计的益生菌方法来解决肥胖症的紧迫问题,即在减肥治疗(包括 GLP-1 受体激动剂)的同时保持肌肉。欲了解更多信息,请访问。

Elevai Research: a research and development subsidiary, currently utilizing Canadian research grants and partnering with leading Canadian Universities to push the boundaries of innovation

Elevai Research:一家研发子公司,目前利用加拿大的研究补助金,并与加拿大领先大学合作,以突破创新的界限

PMGC Capital LLC: a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.

PMGC Capital LLC:一种多策略投资工具,从事投资、贷款和在各个市场寻求多元化投资机会。

The current subsidiaries and pending opportunities underscore PMGC's focus on thinking bigger and its drive to build a growth-oriented portfolio.

目前的子公司和悬而未决的机会凸显了PMGC专注于更大的思维以及其建立以增长为导向的投资组合的动力。

About PMGC Holdings Inc.

关于 PMGC Holdings Inc.

PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries. Currently, our portfolio consists of three wholly owned subsidiaries: Elevai Biosciences Inc., Elevai Research Inc., and PMGC Capital LLC. We are committed to exploring opportunities in multiple sectors to maximize growth and value. For more information, please visit .

PMGC Holdings Inc. 是一家多元化的控股公司,通过跨行业的战略收购、投资和开发来管理和扩大其投资组合。目前,我们的投资组合由三家全资子公司组成:Elevai Biosciences Inc.、Elevai Research Inc.和PMGC Capital LLC。我们致力于探索多个领域的机会,以最大限度地提高增长和价值。欲了解更多信息,请访问。

Forward-Looking Statements

前瞻性陈述

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "believes," "expects," "plans," "potential," "would" and "future" or similar expressions such as "look forward" are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in PMGC Holdings' filings with the United States Securities and Exchange Commission ("SEC"), including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

本新闻稿中有关非历史事实事项的陈述是经修订的1995年《私人证券诉讼改革法》所指的 “前瞻性陈述”。诸如 “相信”、“期望”、“计划”、“潜力”、“将” 和 “未来” 之类的词语或 “展望未来” 等类似表述旨在识别前瞻性陈述。前瞻性陈述是截至本新闻稿发布之日作出的,既不是历史事实,也不是对未来表现的保证。相反,它们仅基于我们当前对业务未来、未来计划和战略、预测、预期事件和趋势、经济、监管机构活动和未来监管以及其他未来条件的信念、预期和假设。由于前瞻性陈述与未来有关,因此它们会受到固有的不确定性、风险和环境变化的影响,这些变化难以预测,其中许多是我们无法控制的。尽管公司认为这些前瞻性陈述中表达的预期是合理的,但它无法向您保证此类预期是正确的,公司提醒投资者,实际业绩可能与预期业绩存在重大差异。因此,您不应依赖这些前瞻性陈述中的任何一项。PMGC Holdings向美国证券交易委员会(“SEC”)提交的文件中对这些风险和其他风险进行了更全面的描述,包括该公司于2024年3月29日向美国证券交易委员会提交的截至2023年12月31日年度的10-k表年度报告的 “风险因素” 部分,以及随后向美国证券交易委员会提交或提供给美国证券交易委员会的其他文件。我们敦促投资者和证券持有人在美国证券交易委员会的网站www.sec.gov上免费阅读这些文件。本新闻稿中包含的所有前瞻性陈述仅代表其发布之日。除非法律要求,否则公司没有义务更新此类声明以反映在声明发表之日后发生的事件或存在的情况。

IR Contact:
IR@pmgcholdings.com

投资者关系联系人:
IR@pmgcholdings.com


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发